Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Best Stocks & ETFs for Artificial Intelligence

Published 07/31/2021, 06:00 AM
Updated 07/09/2023, 06:31 AM

In this episode of ETF Spotlight, I speak with Zacks Senior Stock Strategist, Kevin Cook, about investing in advanced technologies, which are bringing science fiction to our offices, homes, cars, and portfolios.

London-based research company DeepMind, which was acquired by Alphabet (NASDAQ:GOOGL) parent Google (GOOGL) in 2014, has developed an AI system that can predict the 3D shape of all known proteins with almost perfect accuracy. This is a huge development for life sciences and medicine.

Exponential advancements in AI have changed the nature of computing, making Moore’s law irrelevant. Per WSJ, Huang’s law named for NVIDIA’s (NVDA) CEO, is in full effect now. We talk about NVIDIA and the rise of GPU computing.

Advanced Micro Devices (NASDAQ:AMD) (AMD) is surging to all-time highs after reporting as the chip maker continues to take market share from Intel (NASDAQ:INTC). Cadence Design (NASDAQ:CDNS) Systems (CDNS) produces software that designs and builds semiconductors.

The Invesco QQQ (QQQ) and NASDAQ 100 ETF (QQQM), QQQ’s cheaper version, are the best ETFs to get exposure to many highly innovative companies working on advanced technologies.

The iShares Robotics And Artificial Intelligence Multisector ETF (IRBO), ARK Autonomous Technology & Robotics ETF (ARKQ), ROBO Global Artificial Intelligence ETF (THNQ), Global X Artificial Intelligence & Technology ETF (AIQ) are also worth a look.

Tune in to the podcast to learn more.

Make sure to be on the lookout for the next edition of the ETF Spotlight and remember to subscribe! If you have any comments or questions, please email podcast@zacks.com.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

(In full disclosure, Neena owns shares of IRBO in the ETF Investor Portfolio.)


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report

NVIDIA Corporation (NASDAQ:NVDA): Free Stock Analysis Report

Cadence Design Systems, Inc. (CDNS): Free Stock Analysis Report

Invesco QQQ (QQQ): ETF Research Reports

Alphabet Inc. (GOOGL): Free Stock Analysis Report

ARK Autonomous Technology & Robotics ETF (ARKQ): ETF Research Reports

Global X Artificial Intelligence & Technology ETF (AIQ): ETF Research Reports

iShares Robotics and Artificial Intelligence Multisector ETF (IRBO): ETF Research Reports

ROBO Global Artificial Intelligence ETF (THNQ): ETF Research Reports

Invesco NASDAQ 100 ETF (QQQM): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.